Skip to contentI
iBio, Inc.
I
IBIOiBio, Inc. Q3 2021 · 10-Q
Revenue$765.00K$765.00K+696.9% vs Q3 2020 Net Income-$7.66M-$7.66MN/M vs Q3 2020 EPS Diluted-$0.04-$0.04N/M vs Q3 2020 Gross Profit$272,000+2,620.0% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
iBio, Inc. · CIK 1420720 · Engraved from SEC EDGAR
Operating Cash Flowderived-$7,349,000N/M Free Cash Flowderived-$8,342,000N/M Margins · derivedGross margin35.6%+25.1 pt vs Q3 2020
Operating margin-941.6%+3291.8 pt vs Q3 2020
Net margin-1001.4%+3869.4 pt vs Q3 2020
ended Mar 31, 2021 · filed May 17, 2021 · 47 d after period end